Patients BIO 2025: Planning, not panic, as BIO weighs in on US vaccin... At BIO 2025, vaccines were top of mind as a result of recent actions by HHS. Speakers addressed news head on, but also explored the larger context.
News After setback, Rhythm gets good news on Imcivree from FDA Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.